Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

The Dolly-Dollar Dichotomy: Animal Cloning Restrictions and the Competitiveness of the European Biotech Industry

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

image of Nordic Journal of International Law

Objective: Review of animal cloning legislation (legal restrictions) and its potential impact on the competitiveness of the European biotech industry.

Material and methods: Review and comparison of enacted and pending international legislation on animal cloning techniques (US and EU), analyzing materials obtained by database searches and direct contact with EU and US officials. Market prices on therapeutic hormones were provided by Apoteksbolaget, Sweden. The estimations for the production capacity of transgenic animals are based on information from Genzyme USA, and include results obtained from a review of international articles on animal cloning.

Results: Recent scientific and technological progress in modern cloning techniques holds promise to be able to produce an increased amount of cheaper human therapeutics (growth hormone, factor IX, etc.) in the near future. Animal cloning restrictions, as recently introduced in Holland, could thus, if spread to other EU Member States, have a stigmatizing effect upon these developments. This, of course, would have serious implications for the competitiveness of the European biotech industry, reducing the expected employment potential in this field. The European situation can be usefully compared with the developments in the US, where no animal cloning restriction is foreseen in the currently debated US cloning legislation, which refers exclusively to human cloning restrictions. A relocation of the European biotech industry to the US has already been reported on, a process that would, if continued, subsequently diminish the European potential for influencing future developments in the area.

Affiliations: 1: M.D., Researcher, Division of Forensic Medicine, Department of Community Health, University of Lund


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
    Nordic Journal of International Law — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation